Background: The receptor for advanced glycation end products (RAGE) is a pattern-recognition receptor involved in the pathogenesis of inflammatory diseases. However, the significance of the soluble isoform of RAGE (sRAGE) has not been clarified in critical illness. We investigated circulating sRAGE in blood samples from septic patients.
Methods: In this cross-sectional study, criteria for inclusion were patients with severe sepsis and age older than 18 years. Samples were collected within 24 hours after the diagnosis of sepsis and also from healthy volunteers. The levels of sRAGE and RAGE signaling pathway-associated biologic parameters were measured with an enzyme-linked immunosorbent assay kit. Acute Physiology and Chronic Health Evaluation II (APACHE II) and Sequential Organ Failure Assessment (SOFA) scores were calculated at the time of patient enrollment. We used the International Society of Thrombosis and Haemostasis (ISTH) overt disseminated intravascular coagulation (DIC) diagnostic criteria algorithm to assess coagulopathy.
Results: Included were 24 septic patients and 12 healthy volunteers. Serum sRAGE level was significantly increased in the patients compared with healthy controls. Significant correlations were found between sRAGE levels and APACHE II, SOFA, and ISTH DIC scores. The increase in sRAGE levels also correlated with the upregulation of interleukin-6, soluble vascular adhesion molecule 1, and plasminogen activator inhibitor 1 levels and a reduction in platelet count. The fraction of sRAGE other than the endogenous secreted form of RAGE (esRAGE) was augmented in the patients.
Conclusion: We demonstrated for the first time that the serum level of sRAGE increased with the progression of DIC and the severity of sepsis, suggesting that circulating sRAGE reflects RAGE signaling pathway activity, which induces the excessive inflammatory response involved in endothelial injury and coagulopathy and that its measurement may be useful as a biomarker for sepis.
Level Of Evidence: Prognostic study, level IV.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/TA.0000000000000651 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Success of an Inpatient Rehabilitation Program in Subjects with Type 2 Diabetes Mellitus with or Without Metabolic Syndrome.
Biomolecules
November 2024
Ludwig Boltzmann Institute for Arthritis and Rehabilitation, 5760 Saalfelden, Austria.
Introduction: Type 2 diabetes mellitus (T2DM) comprises heterogeneous disorders, which have an increase in blood glucose concentrations in common. Metabolic syndrome (MetS) describes the simultaneous occurrence of several clinical symptoms that increase the risk of cardiovascular disease and T2DM, although T2DM itself is also considered a risk factor for developing MetS.
Objective: This study aimed to identify parameters related to rehabilitation success and relevant to MetS in T2DM patients.
A Novel RAGE Modulator Induces Soluble RAGE to Reduce BACE1 Expression in Alzheimer's Disease.
Adv Sci (Weinh)
January 2025
School of Pharmacy, Sungkyunkwan University, Suwon, 16419, Republic of Korea.
β-secretase (BACE1) is instrumental in amyloid-β (Aβ) production, with overexpression noted in Alzheimer's disease (AD) neuropathology. The interaction of Aβ with the receptor for advanced glycation endproducts (RAGE) facilitates cerebral uptake of Aβ and exacerbates its neurotoxicity and neuroinflammation, further augmenting BACE1 expression. Given the limitations of previous BACE1 inhibition efforts, the study explores reducing BACE1 expression to mitigate AD pathology.
View Article and Find Full Text PDFEffects of Probucol on plasma amyloid-β transport in patients with hyperlipidemia: a 12-week randomized, double-blind, placebo-controlled trial.
Lipids Health Dis
December 2024
Department of Neurology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Background: Although dyslipidemia has been acknowledged as a risk factor for Alzheimer's disease (AD), the effects of lipid-lowering drugs on AD have not been determined. The primary pathophysiological hallmark of AD is the deposition of amyloid-β (Aβ) plaques in the brain. Plasma Aβ levels are influenced by the transport of Aβ from the central nervous system to the peripheral blood.
View Article and Find Full Text PDFAre the Soluble Receptors sRAGE, sRANKL, and Osteoprotegerin Associated with Anemia in Rheumatoid Arthritis?
Int J Mol Sci
November 2024
Department of Medical Biochemistry, Faculty of Pharmacy, Medical University of Plovdiv, 15A Vasil Aprilov Blvd., 4002 Plovdiv, Bulgaria.
Article Synopsis
- Rheumatoid arthritis (RA) is an autoimmune disease that can cause inflammation and lead to anemia, and this study explores how certain soluble receptors are affected in different RA patient subgroups based on anemia types and iron levels.
- The findings show higher levels of sRAGE and sRANKL in patients with anemia of chronic disease combined with iron deficiency anemia (ACD/IDA), while OPG levels decreased, indicating potential differences in disease effects between anemia types.
- The study concludes that soluble receptors like sRAGE, sRANKL, and OPG could serve as biomarkers in RA patients, helping to identify those at risk for anemia and better understand the condition's progression.
Salivary advanced glycated end products, their receptors, and aMMP-8 in periodontitis patients with varying glycemic levels: A cross-sectional study.
J Periodontol
December 2024
Department of Oral and Maxillofacial Diseases, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Background: Advanced glycation end products (AGE) and their receptors (RAGE) have been implicated in developing periodontal complications in diabetic patients. This study aimed to identify salivary AGE, RAGE, soluble RAGE (sRAGE), and active-matrix metalloproteinase-8 (aMMP-8) levels at varying glycemic levels in periodontitis patients.
Methods: Ninety-eight participants were categorized into uncontrolled DM-PD group (n = 27)-periodontitis patients with uncontrolled Type 2 diabetes mellitus (T2DM) (glycated hemoglobin [HbA1c] ≥7%); controlled DM-PD group (n = 33)-periodontitis patients with controlled T2DM (HbA1c 5.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!